National Research Beats Analyst Estimates on EPS

Before you go, we thought you'd like these...
Before you go close icon

National Research (NAS: NRCI) filed its 10-K on March 1. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), National Research met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly, and GAAP earnings per share grew significantly.

Margins expanded across the board.

Revenue details
National Research chalked up revenue of $19.1 million. The one analyst polled by S&P Capital IQ expected sales of $19.1 million on the same basis. GAAP reported sales were 20% higher than the prior-year quarter's $15.9 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.46. The two earnings estimates compiled by S&P Capital IQ anticipated $0.40 per share. GAAP EPS of $0.46 for Q4 were 100% higher than the prior-year quarter's $0.23 per share.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 62.4%, 180 basis points better than the prior-year quarter. Operating margin was 26.2%, 850 basis points better than the prior-year quarter. Net margin was 16.4%, 650 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $23 million. On the bottom line, the average EPS estimate is $0.65.

Next year's average estimate for revenue is $87.8 million. The average EPS estimate is $2.02.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 101 members rating the stock outperform and five members rating it underperform. Among 42 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give National Research a green thumbs-up, and one give it a red thumbs-down.

The healthcare investing landscape is littered with also-rans and a few major winners. Is National Research prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.

At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners